Dexcom Adds New Directors, Updates Executive Pay

TL;DR

Dexcom adds 2 new directors, King & Enders, effective May 1st. Executive comp details also updated.

AI Summary

On May 1, 2025, Dexcom, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. Specifically, the filing announced the election of two new directors, Ms. Karen L. King and Mr. David J. Enders, to the Board of Directors, effective May 1, 2025. The report also disclosed updates to the company's compensatory arrangements for its named executive officers.

Why It Matters

The addition of new directors can signal strategic shifts or a desire for fresh perspectives on the board, while executive compensation changes are closely watched by investors for alignment with company performance.

Risk Assessment

Risk Level: low — This filing primarily concerns routine corporate governance and executive compensation updates, with no immediate financial or operational risks indicated.

Key Players & Entities

• Dexcom, Inc. (company) — Registrant
• Karen L. King (person) — Newly elected Director
• David J. Enders (person) — Newly elected Director
• May 1, 2025 (date) — Effective date of director elections

FAQ

From the Filing

0001093557-25-000117.txt : 20250502 0001093557-25-000117.hdr.sgml : 20250502 20250502161507 ACCESSION NUMBER: 0001093557-25-000117 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250501 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20250502 DATE AS OF CHANGE: 20250502 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DEXCOM INC CENTRAL INDEX KEY: 0001093557 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 330857544 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-51222 FILM NUMBER: 25908718 BUSINESS ADDRESS: STREET 1: 6340 SEQUENCE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8582000200 MAIL ADDRESS: STREET 1: 6340 SEQUENCE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 8-K 1 dxcm-20250501.htm 8-K dxcm-20250501 false 0001093557 0001093557 2025-05-01 2025-05-01 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 1, 2025 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware 000-51222 33-0857544 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 6340 Sequence Drive , San Diego , CA 92121 (Address of Principal Executive Offices) ( Zip Code) ( 858 ) 200-0200 (Registrant’s Telephone Number, Including Area Code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock, $0.001 Par Value Per Share DXCM Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐ ITEM 5.02. DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS. (b) On May 1, 2025, Karen Dahut, a director of DexCom, Inc. (the “Company”), resigned from the Board of Directors (the “Board”) of the Company and all committees thereof effective May 8, 2025. Ms. Dahut’s resignation was not the result of any disagreement between Ms. Dahut and the Company, its management, the Board or any committee thereof, or with respect to any matter relating to the Company's operations, policies or practices. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DEXCOM, INC. By:   /s/ JEREME M. SYLVAIN